Literature DB >> 7991109

Indolent anti-Hu-associated paraneoplastic sensory neuropathy.

F Graus1, I Bonaventura, M Uchuya, J Valls-Solé, R Reñé, J M Leger, E Tolosa, J Y Delattre.   

Abstract

Paraneoplastic sensory neuropathy (PSN) usually runs a subacute progressive course, leaving the patient with severe sensory dysfunction in weeks to months. We describe five patients with PSN, high titers of anti-Hu antibodies (type 1 antineuronal nuclear autoantibodies), and an indolent clinical course. The patients had a median age of 55 years (range, 41 to 72). Four had small-cell (3) or undifferentiated large-cell (1) lung cancer. Patients presented with mild, asymmetric sensory symptoms; in two, the neuropathy was predominant in the arms. Two patients also had a visceral neuropathy causing gastrointestinal dysfunction. The PSN was stable or progressed very slowly without treatment for a median of 18 months (range, 5 to 32) and remained so after treatment with immunoglobulins (1 patient), chemotherapy (3), or both therapies (1). All patients were ambulatory, leading an independent life up until the time of the last visit or until death from the tumor (2 patients). The median follow-up was 36 months (range, 22 to 52). A paraneoplastic origin should be considered in patients with mild, very slowly progressive sensory neuropathies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991109     DOI: 10.1212/wnl.44.12.2258

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Paraneoplastic Diseases of the Nervous System.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

2.  Clinical evaluation and investigation of neuropathy.

Authors:  Hugh J Willison; John B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

Review 3.  Neurological paraneoplastic syndromes.

Authors:  J Dalmau; J B Posner
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.

Authors:  T Byrne; W P Mason; J B Posner; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.

Authors:  M Uchuya; F Graus; F Vega; R Reñé; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

6.  Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases.

Authors:  A S Winkler; A Dean; M Hu; N Gregson; K R Chaudhuri
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

7.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

8.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

9.  Diagnostic approach to peripheral neuropathy.

Authors:  Usha Kant Misra; Jayantee Kalita; Pradeep P Nair
Journal:  Ann Indian Acad Neurol       Date:  2008-04       Impact factor: 1.383

Review 10.  Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review.

Authors:  Simone Rossi; Elena Merli; Roberto De Giorgio; Roberto D'Angelo; Rita Rinaldi; Gaia Deleonardi; Vincenzo Mastrangelo; Anna Simona Sasdelli; Alessandro Di Federico; Maria Guarino; Vincenzo Donadio; Loris Pironi; Francesco Gelsomino
Journal:  J Neurol       Date:  2021-05-02       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.